PB1921: A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF TAMIBAROTENE/AZACITIDINE VERSUS PLACEBO/AZACITIDINE IN NEWLY DIAGNOSED ADULT PATIENTS SELECTED FOR RARA-POSITIVE HR-MDS (SELECT-MDS-1)

oleh: A. DeZern, G. Marconi, D. Deeren, M. Diez Campelo, M. Lübbert, P. Krishnamurthy, Z. Nagy, G. Basak, A. Jonášová, E. Morozova, K. Geissler, Y. Ofran, H. Kelley, A. Volkert, K. Baker, Q. Kang-Fortner, G. Hodgson, C. Madigan, D. A. Roth, M. Kelly, P. Fenaux